A fruit fly study found 11 human genes affecting dopamine and sleep, including mask and clu, offering insights for treating Parkinson’s, depression, and sleep disorders.

Nuvilex CEO bought 70,000 shares Jan. 5–7, spending $56,600, boosting his stake to 346,250 shares.

STARMED rebrands globally to unify multi-modality healthcare solutions.

Santhera expands AGAMREE access to Asia-Pacific via $205M deal with Nxera Pharma.

Enliven Therapeutics reports promising Phase 1b results for ELVN-001 in treating resistant chronic myeloid leukemia, with 38% achieving major molecular response.

The FDA accepted Camurus’s resubmitted application for Oclaiz, a monthly acromegaly treatment, with a decision expected by June 10, 2026.

Erasca shares jumped 60% on merger rumors with AbbVie, then fell to $4.33 amid uncertainty.

China approves Aizhida, a new once-daily ADHD drug, for children and teens aged 6 and older.

Telix Pharmaceuticals to present its drug pipeline at J.P. Morgan Healthcare Conference on January 12, 2026.

CelLBxHealth names Peter Collins CEO and new directors, effective Jan. 31, to advance cancer diagnostics.